A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
מצבים רפואיים
Advanced Renal Cell Carcinoma (RCC)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Local Institution - 0178, Palo Alto, California, United States
Local Institution - 0117, New Haven, Connecticut, United States
Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
Local Institution - 0177, Miami, Florida, United States
Local Institution - 0126, Orlando, Florida, United States
Local Institution - 0175, Atlanta, Georgia, United States
Local Institution - 0170, Fort Wayne, Indiana, United States
Local Institution - 0124, Iowa City, Iowa, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Local Institution - 0176, Big Rapids, Michigan, United States
Washington University School of Medicine, St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, Hauppauge, New York, United States
Contact: Study coordinator (Sahil Doshi)Local Institution - 0135, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
MUSC Hollings Cancer Center, Charleston, South Carolina, United States
Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
Local Institution - 0158, Salt Lake City, Utah, United States
Local Institution - 0095, Seattle, Washington, United States
Local Institution - 0154, Buenos Aires, Argentina
Local Institution - 0156, Buenos Aires, Argentina
Macquarie University, North Ryde, New South Wales, Australia
GenesisCare St Leonards, St Leonards, New South Wales, Australia
Local Institution - 0011, Herston, Queensland, Australia
Local Institution - 0074, South Brisbane, Queensland, Australia
Local Institution - 0003, Malvern, Australia
Hospital Sirio Libanes, Brasília, Federal District, Brazil
Local Institution - 0007, Calgary, Alberta, Canada
Local Institution - 0109, Montreal, Quebec, Canada
Local Institution - 0009, Montreal, Quebec, Canada
Local Institution - 0105, Santiago, Santiago Metropolitan, Chile
Bradfordhill, Santiago, Santiago Metropolitan, Chile
Local Institution - 0163, Santiago, Chile
Local Institution - 0143, Beijing, Beijing Municipality, China
Local Institution - 0157, Beijing, Beijing Municipality, China
Local Institution - 0182, Guangzhou, Guangdong, China
Local Institution - 0183, Changsha Shi, Hunan, China
Local Institution - 0184, Nanjing, Jiangsu, China
Local Institution - 0188, Shanghai Shi, Shanghai Municipality, China
Local Institution - 0144, Beijing, China
Local Institution - 0052, Cali, Colombia
Local Institution - 0147, Prague, Praha 5, Czechia
Local Institution - 0149, Brno, Czechia
Local Institution - 0150, Hradec Králové, Czechia
Local Institution - 0044, Helsinki, Etelä-Suomen Lääni, Finland
Local Institution - 0029, Turku, Finland
Local Institution - 0060, Vantaa, Finland
Local Institution - 0083, Lille, Nord, France
Local Institution - 0080, Boredeaux, France
Local Institution - 0028, Villejuif, France
Local Institution - 0025, Jena, Thuringia, Germany
Local Institution - 0026, Hamburg, Germany
Local Institution - 0014, Herne, Germany
Local Institution - 0027, München, Germany
Local Institution - 0059, Dublin, Ireland
Local Institution - 0062, Dublin, Ireland
Local Institution - 0139, Verona, Veneto, Italy
Local Institution - 0073, Milan, Italy
Local Institution - 0087, Napoli Campania, Italy
Local Institution - 0180, Kobe, Hyōgo, Japan
Local Institution - 0179, Shiwa-gun Yahaba-cho, Iwate, Japan
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Local Institution - 0078, Toyoma, Toyama, Japan
Kyushu University Hospital, Fukuoka, Japan
Local Institution - 0181, Niigata, Japan
Local Institution - 0046, Monterrey, Nuevo León, Mexico
Local Institution - 0048, Oaxaca City, Mexico
Local Institution - 0122, Puebla City, Mexico
Local Institution - 0049, Tlalpan, Mexico
Local Institution - 0108, Tlalpan, Mexico
Local Institution - 0118, Tlalpan, Mexico
Local Institution - 0103, Cluj-Napoca, Romania
Local Institution - 0161, Craiova, Romania
Local Institution - 0100, Iași, Romania
Local Institution - 0101, Sibiu, Romania
Local Institution - 0112, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0017, Seoul, Seoul-teukbyeolsi, South Korea
Local Institution - 0167, Seoul, South Korea
Local Institution - 0013, Madrid, Spain
Local Institution - 0091, Madrid, Spain
Local Institution - 0043, Seville, Spain
Kantonsspital Graubünden, Chur, Switzerland
HOCH Health Ostschweiz, Sankt Gallen, Switzerland
UniversitätsSpital Zürich, Zurich, Switzerland
Royal Marsden Hospital (Chelsea), London, Kensington and Chelsea, United Kingdom
St Bartholomew's Hospital, London, London, City of, United Kingdom
Local Institution - 0186, Preston, North West, United Kingdom
Local Institution - 0022, Cambridge, United Kingdom
Velindre Cancer Centre, Cardiff, United Kingdom
Local Institution - 0061, Edinburgh, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
Royal Marsden Hospital Sutton, Sulton, Surrey, United Kingdom
מובילי המחקר
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb